<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873872</url>
  </required_header>
  <id_info>
    <org_study_id>PROBIOTIC</org_study_id>
    <nct_id>NCT01873872</nct_id>
  </id_info>
  <brief_title>Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics</brief_title>
  <official_title>Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Vincent's East, Birmingham, Alabama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Master Supplements, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Vincent's East, Birmingham, Alabama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have designed this study to measure the effect of normal flora supplementation, using
      available probiotics, on the incidence of Clostridium difficile-associated diarrhea

      in a population of general inpatients who are receiving antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General medical-surgical patients in a community hospital who are receiving antibiotics, and
      who agree to participate, will be given one of two different probiotics, or placebo. Data
      will be gathered during their hospitalization, and at one and three months following hospital
      discharge. We expect to see a lower incidence of Clostridium difficile-associated diarrhea in
      the probiotic groups when compared to the placebo group. We will also be looking for
      differences between the effects of the two probiotics, which differ in strain types and
      number of colony forming units per dose.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Clostridium difficile associated diarrhea in patients receiving antibiotics</measure>
    <time_frame>Up to six months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Development of Clostridium Difficile Associated Diarrhea</condition>
  <arm_group>
    <arm_group_label>Theralac probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Culturelle probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Theralac probiotic</intervention_name>
    <arm_group_label>Theralac probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Culturelle probiotic</intervention_name>
    <arm_group_label>Culturelle probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Any hospitalized patient who is age 19 or older and receiving
        antibiotics.

        Exclusion Criteria:

          -  Feeding tube in place

          -  Pregnancy

          -  Milk or soy allergy

          -  Sensitivity to lactose

          -  Immunocompromised defined as:

               1. Absolute neutrophil count (ANC) â‰¤ 500 cells/mm3

               2. HIV

               3. Cancer patient receiving chemotherapy or radiation therapy

               4. Immune deficiency

               5. Post organ transplant

        Participants will be withdrawn from the study if they develop any of the exclusion criteria
        during the hospitalization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leanne Phillips, Pharm.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's East</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's East</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Middlebrooks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's East</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Wimberly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's East</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Adams, RPh</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's East</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carrie Castleberry, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's East</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Middlebrooks, MD</last_name>
    <phone>205-380-0848</phone>
    <email>markmiddlebrooks@bellsouth.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Vincent's East</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leanne Phillips, Pharm.D</last_name>
      <phone>205-838-3109</phone>
      <email>leanne.phillips@stvhs.com</email>
    </contact>
    <contact_backup>
      <last_name>Mark Middlebrooks, MD</last_name>
      <phone>205-380-0848</phone>
      <email>markmiddlebrooks@bellsouth.net</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Middlebrooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leanne Phillips, Pharm.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter Ross, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee Wimberly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Adams, RPh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carrie Castleberry, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

